...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >B cells as under-appreciated mediators of non-auto-immune inflammatory disease.
【24h】

B cells as under-appreciated mediators of non-auto-immune inflammatory disease.

机译：B细胞是非自身免疫性炎性疾病的低估介体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

B lymphocytes play roles in many auto-immune diseases characterized by unresolved inflammation, and B cell ablation is proving to be a relatively safe, effective treatment for such diseases. B cells function, in part, as important sources of regulatory cytokines in auto-immune disease, but B cell cytokines also play roles in other non-auto-immune inflammatory diseases. B cell ablation may therefore benefit inflammatory disease patients in addition to its demonstrated efficacy in auto-immune disease. Current ablation drugs clear both pro- and anti-inflammatory B cell subsets, which may unexpectedly exacerbate some pathologies. This possibility argues that a more thorough understanding of B cell function in human inflammatory disease is required to safely harness the clinical promise of B cell ablation. Type 2 diabetes (T2D) and periodontal disease (PD) are two inflammatory diseases characterized by little autoimmunity. These diseases are linked by coincident presentation and alterations in toll-like receptor (TLR)-dependent B cell cytokine production, which may identify B cell ablation as a new therapy for co-affected individuals. Further analysis of the role B cells and B cell cytokines play in T2D, PD and other inflammatory diseases is required to justify testing B cell depletion therapies on a broader range of patients.
机译：B淋巴细胞在许多以未解决的炎症为特征的自身免疫疾病中起作用，事实证明，B细胞消融是一种相对安全有效的治疗此类疾病的方法。 B细胞在自身免疫性疾病中部分作为调节性细胞因子的重要来源，但B细胞细胞因子在其他非自身免疫性炎性疾病中也起着作用。因此，B细胞消融除了在自身免疫性疾病中表现出的功效外，还可能使炎性疾病患者受益。当前的消融药物清除了促炎和抗炎B细胞亚群，这可能出乎意料地加剧了某些疾病。这种可能性认为，需要更透彻的了解人类炎症性疾病中的B细胞功能，才能安全地利用B细胞消融的临床前景。 2型糖尿病（T2D）和牙周疾病（PD）是两种炎症性疾病，其自身免疫性较低。这些疾病是由同时出现和Toll样受体（TLR）依赖的B细胞细胞因子产生的变化联系在一起的，这可能将B细胞消融鉴定为共同感染个体的新疗法。需要进一步分析B细胞和B细胞因子在T2D，PD和其他炎症性疾病中的作用，以证明在更广泛的患者上测试B细胞耗竭疗法的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号